Alpha Cognition Inc. (ACOG)

NASDAQ: ACOG · Real-Time Price · USD
10.09
+1.66 (19.69%)
At close: May 29, 2025, 4:00 PM
10.00
-0.09 (-0.89%)
After-hours: May 29, 2025, 7:54 PM EDT
19.69%
Market Cap 161.64M
Revenue (ttm) 2.93M
Net Income (ttm) -11.64M
Shares Out 16.02M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,108
Open 8.68
Previous Close 8.43
Day's Range 8.68 - 10.09
52-Week Range 3.75 - 11.40
Beta 2.49
Analysts Strong Buy
Price Target 20.00 (+98.22%)
Earnings Date May 15, 2025

About ACOG

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the trea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country Canada
Stock Exchange NASDAQ
Ticker Symbol ACOG
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to one analyst, the rating for ACOG stock is "Strong Buy" and the 12-month stock price forecast is $20.0.

Price Target
$20.0
(98.22% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alpha Cognition: Launching A Differentiated Drug Into A Large Alzheimer's Market Opportunity

Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifyi...

10 days ago - Seeking Alpha

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 20...

10 days ago - Newsfile Corp

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

Alpha Cognition Inc. (NASDAQ:ACOG) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Pa...

14 days ago - Seeking Alpha

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the first quarter ended March 31, 2025...

14 days ago - Business Wire

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will ann...

4 weeks ago - Business Wire

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Grapevine, Texas--(Newsfile Corp. - April 30, 2025) - Alpha Cognition, Inc. (NASDAQ: ACOG), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, ...

4 weeks ago - Newsfile Corp

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (the “Company” or “Alpha Cognition”) today announced three upcoming presentations at the 2025 Alzheimer's Ass...

4 weeks ago - Business Wire

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

VANCOUVER & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neu...

7 weeks ago - Business Wire

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a s...

2 months ago - Newsfile Corp

Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript

Alpha Cognition Inc. (NASDAQ:ACOG) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Henry Du - Interim Chief Financial Officer Michael McFadden - Chief Executive Office...

2 months ago - Seeking Alpha

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”) today announced its financial results for the fourth quarter and full year ended...

2 months ago - Business Wire

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...

2 months ago - Business Wire

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announce...

2 months ago - Business Wire

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

VANCOUVER--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerativ...

3 months ago - Business Wire

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Dallas, Texas--(Newsfile Corp. - January 30, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition In...

4 months ago - Newsfile Corp

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies fo...

4 months ago - Business Wire

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition, Inc. (Nasdaq: ACOG) (“ACI” or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurode...

5 months ago - Business Wire

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call

DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerati...

5 months ago - Business Wire

Alpha Cognition Announces Partial Exercise of Over-allotment Option

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies fo...

5 months ago - Business Wire

CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)

Toronto, Ontario--(Newsfile Corp. - Le 16 décembre/December 2024) - The common shares of Alpha Cognition Inc. will be delisted from the CSE at market close December 17, 2024. Alpha Cognition will cont...

5 months ago - Newsfile Corp

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company's listing on the Nasdaq ...

6 months ago - Business Wire

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapi...

6 months ago - Business Wire

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debil...

6 months ago - Business Wire

Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies...

7 months ago - Business Wire